The most likely candidate for repurposing as an anticancer

Treating cancer cell lines with digoxin resulted in cytotoxicity in numerous kinds of cancer cells which includes prostate, breast, renal, and lung cancers, melanoma, and leukemia.39 Notably, the IC50 of this drug in tests with all the aforementioned cancer cells isOncoTargets and Therapy 2017:DovepressDovepressTargeted remedy of Os associated to protein patternsTable 5 Up-regulated proteins and targets of FDa-approved antineoplastic drugsGene DNMT1 ERBB2 Protein name Dna (cytosine-5)methyltransferase 1 receptor tyrosine-protein kinase erbB-2 FDA-approved drug azacitidine (Vidaza) Decitabine (Dacogen) Trastuzumab (hercePTin) lapatinib (Tycerb) Illness indicationa Myelodysplastic syndrome, chronic myelomonocytic leukemia Myelodysplastic syndrome her2-positive breast cancer sophisticated or metastatic breast cancer whose tumors overexpress her2 and who've received prior therapy including an anthracycline, a taxane, and trastuzumab her2-positive, metastatic breast cancer individuals that have already utilised taxane and/or trastuzumab for metastatic illness or had their cancer recur within six months of adjuvant treatment The first-line treatment of patients with metastatic NSCLC whose tumors have egFr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an FDa-approved test in combination with trastuzumab and docetaxel for the remedy of sufferers with her2-positive metastatic breast cancer that have not received prior anti-her2 therapy or chemotherapy for metastatic disease Brain tumors, many purchase NBI30775 myeloma, hodgkin's illness, and non-hodgkin's lymphomas cutaneous T-cell lymphoma cutaneous T-cell lymphoma with at least one prior systemic therapy ALL, GIST, dermatofibrosarcoma protuberans, CML, myelodysplastic syndrome Preladenant advance renal cell carcinoma, some hepatocellular carcinoma Metastatic renal cell carcinoma, gisT (no response to imatinib), pancreatic neuroendocrine tumor advanced renal cell carcinoma, sophisticated soft tissue sarcoma all, cMl advanced renal cell carcinoma cMl locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Medullary thyroid cancer and sufferers with sophisticated rcc who have received prior antiangiogenic therapy locally sophisticated or metastatic nsclc that may be alK good as detected by an FDa-approved test advance renal cell carcinoma sophisticated renal cancer, subependymal giant cell astrocytoma, br.The probably candidate for repurposing as an anticancer agent. Treating cancer cell lines with digoxin resulted in cytotoxicity in many varieties of cancer cells like prostate, breast, renal, and lung cancers, melanoma, and leukemia.39 Notably, the IC50 of this drug in tests using the aforementioned cancer cells isOncoTargets and Therapy 2017:DovepressDovepressTargeted therapy of Os connected to protein patternsTable five Up-regulated proteins and targets of FDa-approved antineoplastic drugsGene DNMT1 ERBB2 Protein name Dna (cytosine-5)methyltransferase 1 receptor tyrosine-protein kinase erbB-2 FDA-approved drug azacitidine (Vidaza) Decitabine (Dacogen) Trastuzumab (hercePTin) lapatinib (Tycerb) Disease indicationa Myelodysplastic syndrome, chronic myelomonocytic leukemia Myelodysplastic syndrome her2-positive breast cancer sophisticated or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab her2-positive, metastatic breast cancer sufferers that have already applied taxane and/or trastuzumab for metastatic disease or had their cancer recur inside 6 months of adjuvant therapy The first-line remedy of individuals with metastatic NSCLC whose tumors have egFr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an FDa-approved test in mixture with trastuzumab and docetaxel for the therapy of sufferers with her2-positive metastatic breast cancer who've not received prior anti-her2 therapy or chemotherapy for metastatic disease Brain tumors, many myeloma, hodgkin's illness, and non-hodgkin's lymphomas cutaneous T-cell lymphoma cutaneous T-cell lymphoma with at least one particular prior systemic therapy ALL, GIST, dermatofibrosarcoma protuberans, CML, myelodysplastic syndrome advance renal cell carcinoma, some hepatocellular carcinoma Metastatic renal cell carcinoma, gisT (no response to imatinib), pancreatic neuroendocrine tumor advanced renal cell carcinoma, sophisticated soft tissue sarcoma all, cMl sophisticated renal cell carcinoma cMl locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Medullary thyroid cancer and sufferers with sophisticated rcc who have received prior antiangiogenic therapy locally sophisticated or metastatic nsclc that is certainly alK positive as detected by an FDa-approved test advance renal cell carcinoma advanced renal cancer, subependymal giant cell astrocytoma, br.